|Day's range||5.50 - 5.70|
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.